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Previewsgenes were mutated in more than one
tumor, the authors estimated that only
ten genes were mutated at statistically
significant rates. However, they attached
significance to identical mutations occur-
ring in different tumors, functionally
related mutations in a pathway (e.g.,
NFKB-activating mutations), clinically
relevant mutations (e.g., BRAF, including
some that were V600E), histone-modi-
fying enzymes, and mutations that might
impact microenvironment interactions.
Finally, a recent study used whole-tran-
scriptome paired-end sequencing to
identify fusion transcripts (Steidl et al.,
2011). The authors initially identified 14
and five predicted fusion transcripts,
respectively, in two Hodgkin’s lymphoma
(HL) cell lines. They then focused on
fusions involving CIITA and identified
recurrent translocations that fused the 50
end of CIITA to multiple partner genes in
15% of HL and 38% of primary medias-
tinal B cell lymphoma (PMBCL), which
phenotpically is related to HL, but in only
3% of DLBCL. Additional studies showed
that the hybrid protein made from the
fusion transcripts had several potential
effects on tumor-microenvironment inter-
actions that favored survival of the tumor.
Comprehensive genome analysis is
identifying important genetic abnormali-ties in hematologicmalignancies. Regard-
less, distinguishing driver and passenger
mutations remains a daunting task. In
these early studies of hematopoietic
tumors, most putative driver mutations
arepresent in only a small fractionof tumor
cells, suggesting great molecular diversity
even for an apparently single clinical
disease. Clearly, many additional samples
will need tobesequenced toobtain amore
complete picture. However, it will be
important to focus also on changes other
than nonsynonymous coding changes,
e.g., mutations in regulatory regions,
structural variationswith long-rang effects
on gene expression, and changes in the
expression and forms of noncoding RNA.
Ultimately, to make sense of all these
findings, it will be critical to perform multi-
dimensional analysis of large cohorts of
patients, ideally uniformly treated, with
serial samples collected longitudinally at
different disease stages, and comprehen-
sively analyzed in terms of DNA (including
epigenetic modifications), RNA, and
protein structure and function.
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In the May 26th issue of the New England Journal of Medicine, de Bono et al. report that the inhibition of
androgen synthesis by abiraterone acetate prolonged the survival of men with prostate cancer previously
treated by androgen suppression.HugginsandHodgespresented the results
of what may be the first translational clin-
ical trial of targeted therapy for cancer in
1941, when circulating androgen levels
were reduced by bilateral orchiectomy inmen with progressive metastatic prostate
cancer (Huggins and Hodges, 1941). To
test the benefit of castration, changes in
serum acid phosphatase, a biomarker of
prostate cancer, and in alkaline phosha-tase, a biomarker of bone destruction
at metastatic sites, were monitored,
revealing marked decreases that accom-
panied improvements in bone pain and
other disease-related symptoms. In theell 20, July 12, 2011 ª2011 Elsevier Inc. 7
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Figure 1. Androgen-Dependent versus Androgen-Independent
Prostate Cancer
The CYP17A inhibitor, abiraterone, can improve outcomes in castration-resis-
tant prostate cancer by further reducing castration levels of androgens. This
provides evidence that castration-resistant prostate cancer can often still be
androgen-dependent. However, ultimately, prostate cancer cells can emerge
that are resistant to abiraterone. Such cells are likely to have a truly androgen-
independent phenotype, in which resistant prostate cancer cells could
continue to express growth and survival pathways through AR-dependent
(e.g., via mutation of AR to allow other ligands to stimulate signaling, via
production of constitutively active AR isoforms lacking the ligand binding
domain, or via subversion of other growth factor receptor pathways for acti-
vating AR signaling), or AR-independent mechanisms. T, testosterone; DHT,
dihydrotestosterone.
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Previewsseven decades since, an-
drogen suppression, now ac-
complished via the use of
gonadotropin-releasing hor-
mone (GnRH) analogs, has
remained the mainstay treat-
ment for advanced prostate
cancer. Yet despite its utility,
androgen suppression almost
always ultimately fails to
control the disease.
More recently, new in-
sights into the molecular
pathogenesis of prostate
cancer, along with a progres-
sive understanding of the
mechanisms underlying pro-
state cancer progression de-
spite androgen suppression,
have led to a new generation
of drugs targeting the an-
drogen signaling axis for
prostate cancer. In normal
prostate epithelial cells, cir-
culating androgens such as
testosterone and dihydrotes-
tosterone bind to the an-
drogen receptor (AR) to
initiate a transcription pro-
gram that drives terminal
differentiation to a columnar
secretory phenotype. Pros-
tate cancer cells coopt an-
drogen signaling to support
growth, survival, and inva-
siveness. Additionally, in a
large subset of prostate can-
cers, chromosomal translo-
cations and deletions in-
volving androgen-regulated
differentiation genes, such
as TMPRSS2, SLC45A3,
and others, create fusions
between the androgen-regu-
lated genes and oncogenes,
rendering the expression of
these malignancy genesunder the control of the AR (Kumar-Sinha
et al., 2008; Palanisamy et al., 2010).
Androgen suppression acts as targeted
therapy for prostate cancer therefore, at
least in part by suppressing the transcrip-
tion of fusion oncogenes.
For many years, the propensity for
prostate cancer to progress despite
androgen suppression was attributed
to the emergence of ‘‘androgen-inde-
pendent’’ prostate cancer cell clones.
However, more recent evidence has re-8 Cancer Cell 20, July 12, 2011 ª2011 Elsevivealed that the cells that foil GnRH treat-
ment have often remained substantially
addicted to androgen signaling, adopting
a ‘‘castration-resistant’’ phenotype that is
not necessarily androgen-independent.
By ablating production of testosterone in
the testes, GnRH analogs and bilateral or-
chiectomy tend to reduce circulating
androgens to a fraction of physiologic
levels but not eliminate the hormones.
Prostate cancer cells addicted to an-
drogen signaling overcome this treatmenter Inc.by: (1) amplification or muta-
tion of the gene encoding the
AR, permitting increased
receptor expression or altered
function, (2) activation of other
cell-signaling pathwaysthat
augment AR transcriptional
trans-activation, and/or (3)
directly synthesizing andro-
genic hormone ligands (Scher
and Sawyers, 2005). Clinical
evidence of this androgen ad-
diction phenotype in the
setting of prostate cancer
progression despite androgen
suppression is provided by
progressive increases in the
serum prostate cancer bio-
marker prostate-specific an-
tigen (PSA), which requires
AR function for expression.
To exploit the persistent
addiction of many prostate
cancers to androgen signaling
despite GnRH treatment, de
Bono et al. (2011) conducted
a clinical trial of abiraterone
acetate, a prodrug for the cy-
tochrome p450 c17 (CYP17)
inhibitor abiraterone, in men
with castration-resistant pros-
tate cancer who had also been
treated with docetaxel che-
motherapy. CYP17 is the crit-
ical enzyme necessary for the
synthesis of androgenic hor-
mones in the testes and else-
where; previous studies had
revealed that the castrate
circulating androgen levels
seen in men on GnRH analogs
could be even further lowered
by abiraterone acetate admin-
istration. The trial enrolled
1195 men with prostate can-
cer who were randomized
in a 2:1 ratio to receive 1 g ofabiraterone acetate or a placebo daily
along with a replacement dose of cortico-
steroid. Results strongly favored the
abiraterone acetate treatment arm, pro-
mpting early study termination after an
interim analysis, with an improvement in
overall survival (with a hazard ratio of
0.65 and a 95% confidence interval of
0.54–0.77), progression-free survival, and
serum PSA response rate (29% versus
6%). Side effects, which were generally
tolerable, included mineralocorticoid-like
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Previewseffects, such as fluid retention, elevated
blood pressure, and low serum potassium
levels. With these data, on April 28, 2011,
theUnited States Food andDrugAdminis-
tration (FDA) approved abiraterone ac-
etate for use in combination with predni-
sone for the treatment of patients with
metastatic castration-resistant prostate
cancer that is progressing despite doce-
taxel chemotherapy.
The utility of abiraterone for castration-
resistant prostate cancer is reminiscent of
the ongoing development of a new gener-
ation of androgen-receptor antagonists,
which attempt to better thwart an-
drogen-signaling in prostate cancer cells
than existing receptor blockers, including
bicalutamide, flutamide, nilutamide, and
cyproterone acetate. One of these new
drugs, MDV3100, interacts with the AR
in castration-resistant prostate cancer
cells in such a way as to interfere with
AR translocation to the cell nucleus,
binding to target genes, and activation of
target gene transcription, effectively
undermining addiction to androgen
signaling. In a clinical trial of this drug for
140 men with castration-resistant pros-
tate cancer, MDV3100 exhibited encour-
aging anticancer activity, with significant
serum PSA declines in 56% of the men
treated (Scher et al., 2010). The clinical
development of MDV3100 has pro-
gressed to pivotal phase 3 trials.
The experience with abiraterone and
MDV3100 underscores the promise of
new drugs targeting androgen signaling
for castration-resistant prostate cancer.
One general limitation of such drugs will
likely be theadverseconsequencesofpro-
longed androgen ablation, including bone
loss and increased cardiovascular risk
that hasbedeviledGnRHtreatment (Saylor
and Smith, 2010). The major ultimate chal-
lenge, however, will almost certainly be theinevitability of disease progression despite
drug treatment. Prostate cancer cells that
emergedespite abirateroneadministration
maywell display a true androgen-indepen-
dentphenotype, manifest in two major
mechanisms: those that continue to use
androgen receptor signaling in an an-
drogen-independent fashion for growth
and survival, and those that are entirely
independent of androgen receptor sig-
naling (Figure 1). Evidence for androgen-
receptor-independent signaling has been
seen in autopsies of men dying of prostate
cancer,where disease deposits have been
found to contain cancer cells devoid of the
AR and its target gene products such as
PSA (Shah et al., 2004). For prostate
cancer cells which are truly androgen-
independent, other signaling pathways
will need to be targeted to control disease
progression.
The availability of abiraterone, which
reversibly reduces circulating androgen
levels much more rapidly than do GnRH
analogs, may facilitate the development
of cyclical approaches to manipulate
androgen signaling in prostate cancer
cells to improve treatment effectiveness.
Already a clinical study of such an
approach, in which GnRH analogs and
testosterone were rapidly cycled along
with docetaxel chemotherapy in men
with non-castrate-resistant prostate can-
cer, has been reported (Rathkopf et al.,
2008). The recognition that the initiation
of transcription at AR target genes in
prostate cancer cells triggers DNA double
strand breaks mediated by TOP2B, a type
2 DNA topoisomerase, has prompted the
idea that the targeted induction of such
genome damage might kill prostate
cancer cells (Haffner et al., 2011). A treat-
ment approach in which abiraterone
administration liberates AR from its sites
in the genome, and then a subsequentCancer Candrogen bolus drives AR back to such
sites, creating DNA strand breaks, could
lead to an opportunity for the use of
agents that sensitize cells containing
DNA strand breaks to apoptosis, such
as poly(ADP-ribose) polymerase (PARP)
inhibitors and other DNA repair antago-
nists (Haffner et al., 2011). In this way,
when sequenced with an androgen
signaling antagonist, AR agonists might
become targeted drugs for castration-
resistant prostate cancer.
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